Whalesbook
Eli Lilly has received marketing authorization from India's drug regulator, the Central Drugs Standard Control Organization (CDSCO), for its Alzheimer's drug, donanemab. This new therapy targets amyloid protein buildup in the brain, offering hope for adults in the early symptomatic stages of Alzheimer's, including mild cognitive impairment and early-stage dementia. The approval marks a significant step in addressing the growing Alzheimer's burden in India.